Search for other papers by Yusuf Emre Ozdemir in
Current site
Google Scholar
PubMed
Search for other papers by Burak Kizilcay in
Current site
Google Scholar
PubMed
Search for other papers by Muge Sonmezisik in
Current site
Google Scholar
PubMed
Search for other papers by Muhammet Salih Tarhan in
Current site
Google Scholar
PubMed
Search for other papers by Deniz Borcak in
Current site
Google Scholar
PubMed
Search for other papers by Meryem Sahin Ozdemir in
Current site
Google Scholar
PubMed
Search for other papers by Osman Faruk Bayramlar in
Current site
Google Scholar
PubMed
Search for other papers by Zuhal Yesilbag in
Current site
Google Scholar
PubMed
Search for other papers by Sevtap Senoglu in
Current site
Google Scholar
PubMed
Search for other papers by Habip Gedik in
Current site
Google Scholar
PubMed
Search for other papers by Hayat Kumbasar Karaosmanoglu in
Current site
Google Scholar
PubMed
Search for other papers by Kadriye Kart Yasar in
Current site
Google Scholar
PubMed
Abstract
We aimed to compare vaccinated and unvaccinated patients hospitalized with COVID-19 in terms of disease severity, need for intensive care unit (ICU) admission, and death. In addition, we determined the factors affecting the COVID-19 severity in vaccinated patients. Patients aged 18–65 years who were hospitalized for COVID-19 between September and December 2021 were retrospectively analyzed in three groups: unvaccinated, partially vaccinated, and fully vaccinated.
A total of 854 patients were included. Mean age was 47.9 ± 10.6 years, 474 patients (55.5%) were male. Of these, 230 patients (26.9%) were fully vaccinated, 97 (11.3%) were partially vaccinated, and 527 (61.7%) were unvaccinated. Of the fully vaccinated patients, 67% (n = 153) were vaccinated with CoronaVac and 33% (n = 77) were vaccinated with Pfizer-BioNTech. All patients (n = 97) with a single dose were vaccinated with Pfizer-BioNTech. One hundred thirteen (13.2%) patients were transferred to ICU. A hundred (11.7%) patients were intubated and 77 (9.0%) patients died. Advanced age (P = 0.028, 95% CI = 1.00–1.07, OR = 1.038) and higher Charlson Comorbidity Index (CCI) (P < 0.001, 95% CI = 1.20–1.69, OR = 1.425) were associated with increased mortality, while being fully vaccinated (P = 0.008, 95% CI = 0.23–0.80, OR = 0.435) was associated with survival in multivariate analysis. Full dose vaccination reduced the need for ICU admission by 49.7% (95% CI = 17–70) and mortality by 56.5% (95% CI = 20–77). When the fully vaccinated group was evaluated, we found that death was observed more frequent in patients with CCI>3 (19.1 vs 5.8%, P < 0.01, OR = 3.7). Therefore, the booster vaccine especially in individuals with comorbidities should not be delayed, since the survival expectation is low in patients with a high comorbidity index.
-
1.
WHO coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int/ [Accessed 30 July 2022].
-
2.
Walker PGT, Whittaker C, Watson OJ, Baguelin M, Winskill P, Hamlet A, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science 2022; 369(6502): 413–422.
-
3.
Bruxvoort KJ, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: Test negative case-control study. BMJ 2021; 375: e068848. Published 2021 Dec 15.
-
4.
Coronavirus (COVID-19) vaccinations. Available from: https://ourworldindata.org/covid-vaccinations [Accessed 30 July 2022].
-
5.
Status of covid-19 vaccination and immunization services in Turkey during the new coronavirus pandemic. Available from: https://www.ttb.org.tr/userfiles/files/yenikoronavirus_pandemisi_surecindeturkiyedecovid19_asilamasi_ve_bagisiklama_hizmetlerinin_durumu.pdf [Accessed 25 May 2022].
-
6.
Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. Lancet Reg Health Am 2021; 1: 100025.
-
7.
Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat Microbiol 2022; 7(3): 379–385.
-
8.
What you need to know about variants. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/about-variants.html [Accessed 11 June 2022].
-
9.
COVID-19 Clinical management: living guidance. Available from: World Health Organization, 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 [Accessed 13 June 2022].
-
10.
Covıd-19 vaccınatıon informatıon platform. Republıc of Turkey Mınıstry of Health. Available from: https://covid19asi.saglik.gov.tr/?_Dil=2 [Accessed 15 June 2022].
-
11.
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K; HEROES-RECOVER Cohorts. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (delta) variant predominance – eight U.S. Locations, December 2020–August 2021. MMWR Morb Mortal Wkly Rep 2021; 70(34): 1167–9. Published 2021 Aug 27.
-
12.
Wu D, Zhang Y, Tang L, Wang F, Ye Y, Ma C, et al. Effectiveness of inactivated COVID-19 vaccines against symptomatic, pneumonia, and severe disease caused by the delta variant: Real world study and evidence – China, 2021. China CDC Weekly 2022; 4(4): 57–65.
-
13.
Surme S, Buyukyazgan A, Bayramlar OF, Cinar AK, Copur B, Zerdali E, et al. Predictors of intensive care unit admission or mortality in patients with coronavirus disease 2019 pneumonia in Istanbul, Turkey. Jpn J Infect Dis 2021; 74(5): 458–64.
-
14.
Ozdemir YE, Balkan II, Bayramlar OF, Alkan S, Murt A, Karaali R, et al. Clinical characteristics of mild-moderate COVID-19 patients and risk factors for the development of pneumonia. Mikrobiyol Bul 2021; 55(3): 342–56.
-
15.
Sezen YI, Senoglu S, Karabela SN, Yesilbag Z, Borcak D, Canbolat Unlu E, et al. Risk factors and the impact of vaccination on mortality in COVID-19 patients. Bratisl Lek Listy 2022; 123(6): 440–3.
-
16.
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021; 384: 1412–23.
-
17.
Villela DAM, de Noronha TG, Bastos LS, Pacheco AG, Cruz OG, Carvalho LM, et al. Effectiveness of mass vaccination in Brazil against severe COVID-19 cases. MedRxiv 2021; 1: 1–25. https://doi.org/10.1101/2021.09.10.21263084.
-
18.
Passarelli-Araujo H, Pott-Junior H, Susuki AM, Olak AS, Pescim RR, Tomimatsu MFAI, et al. The impact of COVID-19 vaccination on case fatality rates in a city in Southern Brazil. Am J Infect Control 2022; 50(5): 491–496. S0196-6553(22)00095-5.
-
19.
Alsaffar WA, Alwesaibi AA, Alhaddad MJ, Alsenan ZK, Alsheef HJ, Alramadan SH, et al. The effectiveness of COVID-19 vaccines in improving the outcomes of hospitalized COVID-19 patients. Cureus 2022; 14(1): e21485. Published 2022 Jan 22.
Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary
Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu
Indexing and Abstracting Services:
- Biological Abstracts
- BIOSIS Previews
- CAB Abstracts
- CABELLS Journalytics
- Chemical Abstracts
- Global Health
- Index Medicus
- Index Veterinarius
- Medline
- Referativnyi Zhurnal
- SCOPUS
- Science Citation Index Expanded
| 2023 | |
|---|---|
| Web of Science | |
| Journal Impact Factor | 1.3 |
| Rank by Impact Factor | Q4 (Immunology) |
| Journal Citation Indicator | 0.31 |
| Scopus | |
| CiteScore | 2.3 |
| CiteScore rank | Q3 (Infectious Diseases) |
| SNIP | 0.389 |
| Scimago | |
| SJR index | 0.308 |
| SJR Q rank | Q3 |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Publication Model | Hybrid |
| Submission Fee | none |
| Article Processing Charge | 1100 EUR/article (only for OA publications) |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2025 | Online subsscription: 772 EUR / 848 USD Print + online subscription: 860 EUR / 944 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Language | English |
| Size | A4 |
| Year of Foundation |
1954 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 1217-8950 (Print) |
| ISSN | 1588-2640 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Jun 2024 | 0 | 64 | 31 |
| Jul 2024 | 0 | 62 | 41 |
| Aug 2024 | 0 | 93 | 39 |
| Sep 2024 | 0 | 74 | 46 |
| Oct 2024 | 0 | 196 | 23 |
| Nov 2024 | 0 | 67 | 15 |
| Dec 2024 | 0 | 10 | 5 |
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.